Agnès Hincelin-Méry

Sanofi (France) — France

Medicine · Health Sciences

8h-index703citations14works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(4), Monoclonal and Polyclonal Antibodies Research(4), Metabolism, Diabetes, and Cancer(4), Diabetes Management and Research(3), Chronic Lymphocytic Leukemia Research(2)

Publications14 total

Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants
Clinical and Translational Science·2023· 28 citedOpen Access
First-in-Human Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAR443820, a Central Nervous System Penetrant RIPK1 Inhibitor in Healthy Participants (S46.005)
Neurology·2023· 1 cited
Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A
PLoS ONE·2019· 19 citedOpen Access
Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients
Frontiers in Immunology·2018· 8 citedOpen Access
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
Seminars in Arthritis and Rheumatism·2018· 56 citedOpen Access
Methotrexate and BAFF interaction prevents immunization against TNF inhibitors
Annals of the Rheumatic Diseases·2018· 30 cited
P008 Methotrexate and baff interaction prevents immunisation against TNF-Α inhibitors by increasing adenosine and regulatory B-cells
Annals of the Rheumatic Diseases·2018Open Access
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
PLoS ONE·2016· 40 citedOpen Access
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
Clinical & Experimental Immunology·2015· 77 citedOpen Access
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
Diabetes Care·2015· 255 cited
ABIRISK Consortium Recommendations for Terms and Definitions for Describing and Interpreting Unwanted Immunogenicity of Biopharmaceuticals
2015
P330 Effets du lixisénatide vs liraglutide sur l’équilibre glycémique, la vidange gastrique et les critères de tolérance du traitement dans le diabète de type 2 (DT2) traité de façon optimisée par insuline glargine ± metformine
Diabetes & Metabolism·2015
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
Diabetes Obesity and Metabolism·2013· 189 citedOpen Access
PO13 Caractéristiques pharmacodynamiques du lixisénatide en une prise quotidienne vs le liraglutide chez des patients ayant un diabète de type 2 (DT2) non équilibré sous metformine
Diabetes & Metabolism·2012

Frequent Co-authors

Marc Pallardy(6), Julie Davidson(5), Xavier Mariette(5), Pierre Dönnes(5), Christoph Kapitza(4), Matthieu Allez(4), Philippe Broët(4), Florian Deisenhammer(4), Aude Gleizes(4), Thomas Först(3), Hans Veit Coester(3), T. Albert(3), Niek de Vries(3), Anna Fogdell‐Hahn(3), Elizabeth C. Jury(3), Sébastien Lacroix‐Desmazes(3), Claudia Mauri(3), Johannes Oldenburg(3), Sebastian Spindeldreher(3), Signe Hässler(3)